Overview
Atogepant is a small-molecule calcitonin gene-related peptide (CGRP) receptor antagonist developed for the preventive treatment of migraines. It was approved by the FDA in 2021 and represents a non-opioid alternative for migraine management. The drug selectively binds to CGRP receptors, inhibiting their activation and reducing the frequency and severity of migraine attacks. Unlike older migraine treatments, atogepant is specifically designed for prevention rather than acute relief. Its oral administration and favorable pharmacokinetic profile make it a convenient option for long-term use. Clinical trials have demonstrated its efficacy in reducing monthly migraine days by up to 50% in some patients.
Physical and Chemical Properties
Atogepant is a white to off-white crystalline powder with a molecular weight of 548.59 g/mol. Its molecular formula is C29H30F2N6O3, indicating a complex structure with fluorine and nitrogen functional groups. The compound is sparingly soluble in water but dissolves well in dimethyl sulfoxide (DMSO) and other polar organic solvents. Stability studies suggest that atogepant should be stored under controlled conditions (2-8°C) to prevent degradation. It exhibits high selectivity for the CGRP receptor, with minimal off-target effects, contributing to its safety profile. The compound’s logP value indicates moderate lipophilicity, which aids in its oral absorption.
Main Applications
Atogepant is primarily used for the preventive treatment of episodic and chronic migraines in adults. It is prescribed to patients who experience four or more migraine days per month. The drug is taken orally once daily, with or without food, making it a user-friendly option compared to injectable CGRP antagonists. In clinical practice, atogepant has shown promise in reducing the frequency, duration, and intensity of migraines. It is particularly beneficial for patients who do not respond well to traditional therapies like beta-blockers or anticonvulsants. Ongoing research is exploring its potential in other neurological conditions involving CGRP pathways.
Safety and Storage
Atogepant is generally well-tolerated, with common side effects including nausea (10-15% of patients), constipation, and fatigue. Severe adverse reactions are rare but may include hypersensitivity reactions. The drug is contraindicated in pregnancy due to potential risks to fetal development. Proper storage is critical to maintain atogepant’s stability. It should be kept in its original packaging at 2-8°C, protected from light and moisture. Bulk pharmaceutical buyers should ensure cold chain logistics during transportation to prevent degradation. Always refer to the manufacturer’s safety data sheet (SDS) for handling guidelines.
B2B Procurement Guide
For B2B buyers, sourcing atogepant requires attention to regulatory compliance and quality assurance. Prioritize suppliers with Good Manufacturing Practice (GMP) certification and request certificates of analysis (CoA) for each batch. Key parameters to verify include purity (≥98% by HPLC), residual solvents, and heavy metal content. Pricing varies based on order volume and supplier location, with bulk purchases (1 kg+) typically offering cost advantages. Lead times can range from 4-12 weeks due to manufacturing complexity. Consider partnering with specialized pharmaceutical distributors to navigate import/export regulations, especially for cross-border transactions.
Related Manufacturers
- 主营：1689-89-0、酒石酸、61438-64-0、阿托吉泮1374248、81810-66-4、17316-67-5、31430-15-6、68786-66-3、42461-84-7、115550-35-1、217500-96-4、101831-37-2、129496-10-2、沃尼妙林、丹诺沙星、非泼罗尼、加米霉素、能霉素钠、达氟沙星、奥苯达唑、粘杆菌素、双氢链霉素、酸泰妙菌素、盐酸四咪唑、盐酸沙拉沙星